Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
Sini, P., Gurtler, U., Zahn, S.K., Baumann, C., Rudolph, D., Baumgartinger, R., Strauss, E., Haslinger, C., Tontsch-Grunt, U., Waizenegger, I.C., Solca, F., Bader, G., Zoephel, A., Treu, M., Reiser, U., Garin-Chesa, P., Boehmelt, G., Kraut, N., Quant, J., Adolf, G.R.(2016) Mol Cancer Ther 15: 2388-2398
- PubMed: 27496137 
- DOI: 10.1158/1535-7163.MCT-16-0066
- Primary Citation of Related Structures:  
5EYK, 5EYM, 5K3Y - PubMed Abstract: 
Although the MAPK pathway is frequently deregulated in cancer, inhibitors targeting RAF or MEK have so far shown clinical activity only in BRAF- and NRAS-mutant melanoma. Improvements in efficacy may be possible by combining inhibition of mitogenic signal transduction with inhibition of cell-cycle progression ...